Heron Therapeuti Total Liabilities
Heron Therapeuti total liabilities. Based on the latest financial reports, Heron Therapeuti (HRTX) has total liabilities worth $237.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Heron Therapeuti's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Heron Therapeuti (1987–2025)
Total liabilities of Heron Therapeuti from 1987 to 2025. This chart illustrates how Heron Therapeuti's total liabilities have evolved over time, based on quarterly financial data.
Heron Therapeuti Competitors by Total Liabilities
The table below lists competitors of Heron Therapeuti ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
Turkey | TL1.89 Billion |
|
Tripar Multivision Plus
JK:RAAM
|
Indonesia | Rp361.61 Billion |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
USA | $10.55 Million |
|
LEIFRAS Co., Ltd. American Depositary Shares
NASDAQ:LFS
|
USA | $2.81 Billion |
|
Covalon Technologies Ltd.
V:COV
|
Canada | CA$6.41 Million |
|
META WOLF AG INH O.N.
F:WOLF
|
Germany | €39.38 Million |
|
Patria Latin American Opportunity
NASDAQ:PLAO
|
USA | $32.94 Million |
Liability Composition Analysis (1987–2025)
This chart breaks down Heron Therapeuti's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Heron Therapeuti total assets.
Liquidity & Leverage Metrics
Heron Therapeuti Total Liabilities Ratios Explained
Heron Therapeuti total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 25.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heron Therapeuti's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heron Therapeuti (1987–2025)
The table below shows the annual total liabilities of Heron Therapeuti from 1987 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $241.54 Million | -9.47% |
| 2024-12-31 | $266.80 Million | +4.02% |
| 2023-12-31 | $256.48 Million | +8.05% |
| 2022-12-31 | $237.38 Million | +4.05% |
| 2021-12-31 | $228.14 Million | +94.88% |
| 2020-12-31 | $117.06 Million | +7.45% |
| 2019-12-31 | $108.95 Million | +18.40% |
| 2018-12-31 | $92.02 Million | -10.81% |
| 2017-12-31 | $103.17 Million | +16.27% |
| 2016-12-31 | $88.73 Million | +349.62% |
| 2015-12-31 | $19.73 Million | +44.90% |
| 2014-12-31 | $13.62 Million | +94.79% |
| 2013-12-31 | $6.99 Million | +68.32% |
| 2012-12-31 | $4.15 Million | +12.48% |
| 2011-12-31 | $3.69 Million | +131.54% |
| 2010-12-31 | $1.59 Million | -25.99% |
| 2009-12-31 | $2.15 Million | -48.71% |
| 2008-12-31 | $4.20 Million | -43.79% |
| 2007-12-31 | $7.48 Million | +43.99% |
| 2006-12-31 | $5.19 Million | +87.71% |
| 2005-12-31 | $2.77 Million | -3.29% |
| 2004-12-31 | $2.86 Million | +51.16% |
| 2003-12-31 | $1.89 Million | -19.15% |
| 2002-12-31 | $2.34 Million | -46.02% |
| 2001-12-31 | $4.33 Million | -25.74% |
| 2000-12-31 | $5.84 Million | -49.24% |
| 1999-12-31 | $11.50 Million | +33.72% |
| 1998-12-31 | $8.60 Million | -38.57% |
| 1997-12-31 | $14.00 Million | +4.48% |
| 1996-12-31 | $13.40 Million | -25.14% |
| 1995-12-31 | $17.90 Million | +52.99% |
| 1994-12-31 | $11.70 Million | -15.83% |
| 1993-12-31 | $13.90 Million | +71.60% |
| 1992-12-31 | $8.10 Million | +26.56% |
| 1991-12-31 | $6.40 Million | +20.75% |
| 1990-12-31 | $5.30 Million | +43.24% |
| 1989-12-31 | $3.70 Million | +5.71% |
| 1988-12-31 | $3.50 Million | -7.89% |
| 1987-12-31 | $3.80 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more